The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study evaluating the use of prydoxine to prevent hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Akiyo Yoshimura
No relevant relationships to disclose
Hiroji Iwata
Honoraria - Chugai Pharma
Takako Hayashi
No relevant relationships to disclose
Naomi Kobayashi
No relevant relationships to disclose
Kanako Saito
No relevant relationships to disclose
Michiko Tsuneizumi
No relevant relationships to disclose
Masataka Sawaki
No relevant relationships to disclose
Masaya Hattori
No relevant relationships to disclose
Takumi Nakada
No relevant relationships to disclose
Isao Yokota
No relevant relationships to disclose
Tatsuya Toyama
No relevant relationships to disclose